Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EcNPAQ
- Development stage
- Preclinical
- Lead developer
- Southern Medical University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
EcNPAQ is an engineered live biotherapeutic product (LBP) consisting of a probiotic consortium based on the *Escherichia coli* Nissle 1917 (EcN) chassis. It is designed for cancer immunotherapy, specifically targeting colorectal cancer by integrating multiple signals from the tumor microenvironment (TME). The consortium utilizes an orthogonal quorum-sensing system to respond to three characteristic TME parameters: low pH, hypoxia, and high lactate levels. Upon activation, it achieves the programmed release of two therapeutic payloads: a lactate depletion enzyme (LdhA) to improve the metabolic environment and a programmed death ligand 1 (PD-L1) nanobody for immune checkpoint inhibition. Preclinical studies in humanized mouse models have demonstrated that EcNPAQ can restructure intestinal microbial ecology, enhance the infiltration of CD8+ and CD4+ T cells, and significantly suppress tumor progression.
- Other names
- engineered probiotic consortiumEcN-based probiotic
02
Targets
L-lactateCD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on EcNPAQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EcNPAQ.